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Abstract
Background: The association of an infectious agent with chronic fatigue syndrome (CFS) has been
difficult and is further complicated by the lack of a known lesion or diseased tissue. Cell-free plasma
DNA could serve as a sentinel of infection and disease occurring throughout the body. This type
of systemic sample coupled with broad-range amplification of bacterial sequences was used to
determine whether a bacterial pathogen was associated with CFS. Plasma DNA from 34 CFS and
55 non-fatigued subjects was assessed to determine plasma DNA concentration and the presence
of bacterial 16S ribosomal DNA (rDNA) sequences.
Results: DNA was isolated from 81 (91%) of 89 plasma samples. The 55 non-fatigued subjects had
higher plasma DNA concentrations than those with CFS (average 151 versus 91 ng) and more CFS
subjects (6/34, 18%) had no detectable plasma DNA than non-fatigued subjects (2/55, 4%), but
these differences were not significant. Bacterial sequences were detected in 23 (26%) of 89. Only
4 (14%) CFS subjects had 16S rDNA sequences amplified from plasma compared with 17 (32%) of
the non-fatigued (P = 0.03). All but 1 of the 23 16S rDNA amplicon-positive subjects had five or
more unique sequences present.
Conclusions: CFS subjects had slightly lower concentrations or no detectable plasma DNA than
non-fatigued subjects. There was a diverse array of 16S rDNA sequences in plasma DNA from both
CFS and non-fatigued subjects. There were no unique, previously uncharacterized or predominant
16S rDNA sequences in either CFS or non-fatigued subjects.
Background
Chronic fatigue syndrome (CFS) is a complex illness de-
fined by unexplained disabling fatigue and a combination
of non-specific accompanying symptoms [1]. There are no
consistent anatomic lesions or clinical chemistry abnor-
malities. While no known infectious agents or immuno-
logic perturbations have been consistently associated with
CFS [2–7], the illness has many features suggestive of an
infectious disease. Fatigue, muscle and joint pain, sore
throat, and swollen glands are all common symptoms
shared by infection and CFS. In addition, many people
with CFS describe the onset of their illness as sudden or
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"flu-like", anecdotally suggesting a possible infectious eti-
ology [8]. However, identification of an infectious agent
specifically associated with CFS has eluded conventional
laboratory analysis. Extensive seroepidemiologic surveys
to detect antibody responses to numerous known viral,
bacterial, and rickettsial agents have failed to show a dif-
ference between CFS cases and normal controls [9,10].
Searching for known or novel infectious agents in persons
with CFS is complicated by the lack of a known lesion or
diseased tissue to sample. Recently, circulating cell-free
DNA from plasma and serum [11] has been shown to con-
tain sequences of tumor [12], viral [13], and bacterial ori-
gin [14]. This plasma DNA therefore serves as a sentinel of
occult disease occurring in diverse sites throughout the
body. We used this plasma DNA to search for previously
uncharacterized as well as known bacterial pathogens. To
do so, we used broad range PCR of the bacterial 16S ribos-
omal RNA gene (rRNA) [15]. This broad range amplifica-
tion scheme has been successful in detecting and
characterizing bacterial pathogens from several disease
states and in several types of clinical specimens [16].
We determined the level of circulating plasma DNA in
CFS subjects as one possible indicator of increased cellular
turnover or chronic inflammation. We also amplified and
sequenced the 16S rRNA gene to search for known and or
previously uncharacterized bacterial agents in cell-free cir-
culating DNA to determine if a bacterial pathogen was as-
sociated with CFS.
Results
Evaluation of methods
We first determined whether the bacterial 16S rDNA se-
quence could be amplified if present in cell-free plasma
DNA. To do this, we spiked 100 ng of plasma DNA with
14 ng to 1.4 × 10-9 ng of purified Escherichia coli template
DNA. As shown in Figure 1, as little as 1.4 × 10-3 ng of E.
coli DNA could be detected after amplification of the 16S
rRNA gene by using the 515F and RD1 primers. This
amount is the equivalent of 1.9 × 102 E. coli genomes per
100 ng cell-free plasma DNA. All amplified products were
sequenced and confirmed to be the same E. coli strain (da-
ta not shown).
Characterization of plasma DNA
The amount of cell-free DNA ranged from 0 to 1320 ng
per ml of plasma (average 128 ng DNA), with 91% (81/
89) having detectable levels. CFS subjects tended to have
less plasma DNA than non-fatigued subjects (average 91
versus 151 ng), but this difference was not significant. Six
(18%) of 34 plasma samples from CFS subjects had no de-
tectable cell-free DNA, whereas only 2 (4%) of 55 non-fa-
tigued subjects had no detectable cell-free DNA in their
plasma (P = 0.08). No differences in plasma DNA concen-
tration were noted between subjects when grouped by sex,
age, CFS onset type, or duration of illness.
All 89 samples, whether plasma DNA was isolated or not,
were evaluated for the presence of bacterial 16S rDNA se-
quences. Overall, 23 (26%) subjects had 16S rDNA se-
quences amplified and characterized. The average number
of distinct 16S rDNA sequences in the 23 subjects was 9
(range 3–14). The CFS subjects had on average 11 distinct
16S rDNA sequences and the non-fatigued subjects had
an average of 9 distinct 16S rDNA sequences. The plasma
DNA of 4 (14%) of 28 CFS subjects had 16S rDNA se-
quences compared with 17 (32%) of 53 of non-fatigued
subjects (P = 0.03). No differences were noted in detection
of bacterial 16S rDNA sequences between subjects when
grouped by sex, age, CFS onset type, or duration of illness.
There was no correlation between the amount of plasma
DNA and the ability to amplify 16S rDNA sequences (Fig-
ure 2) since these sequences were detected in samples
from CFS and non-fatigued subjects with plasma DNA
concentrations that ranged from 24 to 294 ng/ml.
All 16S rDNA-amplified products were sequenced to iden-
tify the prokaryotic origin. Each of the sequences was ei-
ther identical or highly similar (97% or higher) to
prokaryotic sequences in GenBank (data not shown). To
determine whether a particular bacterial sequence was
Figure 1
Titration of E. coli template DNA for 16S rDNA PCR assay, 
using 515F and RD1 primers. Lanes: L, 100-bp DNA ladder; 
1, 14 ng; 2, 1.4 ng; 3, 0.14 ng; 4, 1.4 × 10-2 ng; 5, 1.4 × 10-3 
ng; 6, 1.4 × 10-4 ng; 7, 1.4 × 10-5 ng; 8, 1.4 × 10-6 ng; 9, 1.4 × 
10-7 ng; 10, 1.4 × 10-8 ng; 11, 1.4 × 10-9 ng; 12, Negative con-
trol (sterile distilled water); 13, Positive control (purified E. 
coli DNA).BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/39
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found in CFS cases versus non-fatigued controls, a cluster
analysis was performed. There were no 16S rDNA se-
quences that were unique or predominant in either the
CFS or the non-fatigued group, as indicated by the ran-
dom distribution and lack of clustering of CFS or non-fa-
tigued subjects (Figure 3). There was also no indication
that bacteria known to cause prolonged fatiguing illness
(e.g., Coxiella sp. or Borellia sp.) were more prevalent in
CFS subjects.
Discussion
Since CFS has no known anatomic lesion, we decided to
examine the levels of cell-free plasma DNA as a systemic
indicator of disease. Plasma DNA was isolated from most
of the CFS and non-fatigued subjects. We detected a high-
er concentration of plasma DNA in the non-fatigued sub-
jects than in the CFS subjects and there were fewer non-
fatigued subjects who were plasma DNA negative than
CFS subjects, however, these differences were not signifi-
cant. The physiologic significance and the source of cell-
free DNA in the plasma are not fully appreciated, but we
suspect that it may result from cellular degradation. To
date, plasma DNA has been used as a relatively noninva-
sive sample to detect ongoing pathogenic events, such
minimal residual disease or cancer [10]. Our data show
no significant difference in the level of plasma cell-free
DNA in CFS versus non-fatigued subjects, indicating that
there may be no unusual cell turnover in this population
of CFS subjects. It is also possible that cell-free plasma
DNA concentration is not a sensitive indicator for in-
creased cellular turnover or chronic inflammation.
Despite an exhaustive search for known pathogens by
conventional laboratory methods, no single pathogen has
been consistently identified as a causal agent of CFS. Al-
most every known viral and bacterial agent that can cause
fatiguing illness has been tested for in CFS subjects, and
there has been no difference in the prevalence of these
agents between CFS and healthy subjects [9,17]. One ex-
planation is that the pathogen associated with CFS is nov-
el or previously uncharacterized. To search for prokaryotic
agents that might be specifically associated with CFS, we
used consensus PCR primers to the conserved 16S rRNA
subunit to detect and characterize these sequences. Of the
89 subjects, 4 CFS subjects and 17 non-fatigued subjects
had 16S rDNA sequences amplified. This difference in the
presence or absence of the 16S rDNA amplified product
between CFS and non-fatigued was not related to differ-
ences in plasma DNA concentration. There were no
unique or previously uncharacterized prokaryotic se-
quences identified in either the CFS or non-fatigued
group. Rather, a diverse array of known prokaryotic se-
quences was found circulating in the plasma.
While it is unlikely that the 16S rDNA sequences charac-
terized here are due to experimental or environmental
contamination, we cannot exclude the possibility that the
vacutainer tubes used for blood collection were a source
of bacterial DNA detected. However, the vacutainer tubes
were not likely a significant source since all plasma sam-
ples, whether DNA was present or not, were subjected to
amplification for the 16S ribosomal subunit. All of the
plasma DNA-negative samples were negative for the 16S
rDNA-amplified product. In addition, water controls tak-
en through the entire extraction process were consistently
negative. Finally, only 23 of the 89 plasma samples were
positive for 16S rDNA sequences. If our results are a reflec-
tion of the occurrence of 16S rDNA sequences in healthy
subjects, it is plausible to hypothesize that the presence,
rather than absence, of these sequences reflects the nor-
mal physiologic state and symbiotic relationship between
humans and microbes. This is not the first illustration of
the apparent symbiotic relationship that exists between
humans and bacteria. The assessment of blood from
healthy subjects by amplification of the 16S rRNA gene re-
vealed numerous bacterial sequences that were not found
in reagent controls [18]. Weber et al [19] have identified a
number of microbial and viral transcripts from human
cDNA libraries by computational subtraction method.
Not surprisingly, the human body has been referred to as
Figure 2
Graphical representation of the number of 16S rDNA 
sequences in each subject (primary y axis and represented as 
bars) in relation to the subjects' plasma DNA concentration 
(secondary y axis and represented as points on the line). All 
34 CFS subjects are represented on the left side of the graph 
and all 55 non-fatigued subjects are shown on the right side. 
Each group was sorted from lowest to highest plasma DNA 
concentration to illustrate the lack of correlation between 
DNA concentration and 16S rDNA sequences.
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Figure 3
Cluster analysis of the 23 subjects positive for 16S rDNA sequences from the 300 bp cloned insert to determine whether a 
particular bacterial sequence was found in CFS cases versus non-fatigued controls. The subjects' classification as non-fatigued 
(NF) or CFS is shown at the top of the columns. The identification of the 16S rDNA sequence is shown at the right. The 
colored block indicates the presence and number of clones of that particular bacterial sequence; white is negative, blue is one 
clone, green is two clones, red is three clones, and black is four clones.
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"microbial observatory" [20]. Further analysis of the mi-
crobial flora that exists at various sites within the body in
both healthy and diseased persons should further our un-
derstanding of the interrelationships between microbes
and their human hosts.
The experimental design used for this study has some lim-
itations for addressing our hypothesis that a novel patho-
gen is associated with CFS. The plasma DNA sample may
not be the ideal sample for detecting prokaryotic sequenc-
es. Granulocyte cell subsets may be more appropriate
since this peripheral blood cell fraction contains neu-
trophils and other scavenger cells important for viral and
bacterial clearance. These peripheral blood samples may
not all have been collected and processed optimally for
preservation of DNA in plasma but all samples from all
subjects were processed similarly. Finally, the CFS subjects
were years past the onset of illness and may have cleared
the agent that provided the trigger for illness.
Conclusions
DNA isolated from the plasma can be used to investigate
the association of pathogens with occult disease. Those
CFS subjects with plasma DNA had slightly lower concen-
trations than the non-fatigued subjects and there were
more CFS subjects with no detectable DNA in plasma.
There was a diverse array of 16S rDNA sequences in plas-
ma DNA from both CFS and non-fatigued subjects. Future
assessment of 16S rDNA sequences in peripheral blood
will focus on the granulocyte cell subset.
Subjects and methods
Case and control subjects
As part of a longitudinal population-based study of CFS in
Wichita, Kansas [21], peripheral blood specimens were
collected during clinical evaluation of fatigued subjects
identified as having potential CFS ("CFS-like") and a ran-
dom selection of non-fatigued subjects. Among persons
clinically evaluated at baseline, samples from 34 subjects
who met the 1994 CFS case definition [1] and 55 non-fa-
tigued subjects with sufficient plasma stored were selected
for analysis.
Blood was collected in sodium citrate vacutainer tubes
and shipped by overnight courier to the Centers for Dis-
ease Control and Prevention (CDC) Serum Bank Facility
in Lawrenceville, Georgia. The uncoagulated blood was
diluted 1:2 with physiologic saline and separated on Fi-
coll to collect plasma and mononuclear cells. The diluted
plasma was stored in 1-ml aliquots at -70°C until needed.
Plasma DNA isolation
A 1-ml aliquot of plasma was concentrated to approxi-
mately 250 µl in a Centricon Centrifugal Filter Device YM-
100 (Millipore Corporation, Bedford MA) and DNA was
extracted by using the QIAmp DNA Mini Kit (Qiagen Inc.,
Valencia, CA), according to manufacturers' instructions. A
DyNA Quant 200 Fluorometer (Amersham Biosciences,
Inc., Piscataway, NJ) was used to determine DNA concen-
tration.
Polymerase chain reaction (PCR)
A 50-µl amplification reaction consisted of 5 µl of 10 ×
PCR buffer (100 mM Tris HCl, pH 8.3; 500 mM KCl), 2
mM of MgCl2, 0.2 mM of dATP, dCTP, dGTP, dTTP, 2.5 U
of Taq polymerase, 10 pmol each of forward and reverse
primers, and 5 µl of the template plasma DNA. Water
samples that were taken through the plasma DNA concen-
tration and extraction process were included as samples to
identify background bacterial sequences present in rea-
gents and supplies. Two sets of 16S rDNA primers 515F/
RD1 and 515F/806R [16,17] were used in separate ampli-
fications. These primers yield amplification products of
~1045 and ~300 bp, respectively. The 515F/806R primers
were included to amplify smaller templates and low copy
number targets. The PCR was performed in a PE 9700
thermocycler with an initial incubation at 94°C for 4-
min, followed by 35 cycles of 94°C for 30 sec, 55°C for
30 sec, and 72°C for 90 sec. A final step consisted of a 5-
min extension at 72°C. The amplified products were re-
solved in 1.5% Nusieve agarose gel and photographed un-
der UV light by using a GelDoc 2000 imaging system (Bio-
Rad Laboratories).
16S rDNA sequence determination
The 1045- and 300-bp amplified products were purified
by gel exclusion chromatography to remove unincorpo-
rated nucleotides and enzymes, and then either se-
quenced directly or after cloning into a vector. The direct
sequencing was done with Cy5-labeled, nested sequenc-
ing primers 806R, and 515F in an ALFexpress sequencer
(Amersham Pharmacia). All products amplified with the
515F/806R primer set were cloned into a PGEM-T easy
vector (Promega Corp., Madison, WI) or into a TOPO TA
cloning vector for sequencing (Invitrogen Corp.,
Carlsbad, CA) by following the manufacturer's protocol.
Ninety six clones from each reaction amplified with the
515F/806R primers were selected for further investigation.
Each clone was grown overnight in 2.0 ml of LB broth and
a plasmid miniprep was prepared. Unique clones were de-
termined by PCR-RFLP of the amplified inserts. The in-
serts in the plasmid were amplified in a 30 µl PCR reaction
using T3 and T7 vector based primers followed by double
digestion of the products with MspI and HinPI. The clones
containing unique inserts were identified on the basis of
unique restriction pattern and were selected for sequenc-
ing. Typically, ten to twenty unique restriction patterns
were identified resulting in the sequencing of at least 10
clones from each sample. The plasmid inserts were se-
quenced in both directions using vector-based sequencingPublish with BioMed Central    and   every 
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primers T3, T7, or SP6 in an ABI 377 sequencer (Perkin
Elmer Corp., Norwalk CT).
Data analysis
We used the chi square to identify differences in plasma
DNA concentrations between the CFS and non-fatigued
subjects. Subjects were stratified on the basis of sex, age
(<45 years vs >45 years), CFS onset type (sudden vs grad-
ual), and duration of illness (<5 years vs > 5 years) and
compared by using a non-parametric Wilcoxon two-sam-
ple test. Cluster analysis was accomplished using BioNu-
merics (Applied Maths, Antwerp Belgium). For sequence
analysis, contiguous sequences were generated using the
DNASTAR program for each clone from sense and anti-
sense strand sequences. The GenBank database was
searched by using the BLAST tool to identify bacterial se-
quence similarities. A sequence similarity of 97% or great-
er was considered as an acceptable identification.
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